Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electroless semi-automatic synthesis of <sup>225</sup>Ac-labeled PSMA-derivatives for clinical application and evaluation of rechelation capability.

Nuclear medicine and biology·2026
Same author

Development and structure-guided characterization of a novel ACE2-binding macrocyclic peptide.

Journal of structural biology: X·2026
Same author

Diagnostic Twins: Exploring the Radiohybrid Concept with Iodine-123 and Lanthanum-133 for PSMA-Targeted SPECT and PET Imaging.

Journal of medicinal chemistry·2026
Same author

Validation of Folate Receptor-α Selectivity of 6<i>S</i>-5-Methyltetrahydrofolate-Based Radioconjugates: A Prerequisite for Therapeutic Application?

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Evaluation of folate receptor-alpha and other surface markers as potential targets for radionuclide therapy of ovarian cancer.

EJNMMI research·2025
Same author

Targeted β<sup>-</sup>-Particle Plus Conversion and Auger-Electron Therapy with <sup>161</sup>Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025

Related Experiment Video

Updated: May 19, 2026

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner
08:36

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Published on: June 7, 2024

Single Photon Emission Computed Tomography Tracer.

Hans-Jürgen Pietzsch1, Cristina Müller2,3, Roger Schibli2,3

  • 1Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|May 18, 2026
PubMed
Summary

Developing novel single-photon emission computed tomography (SPECT) tracers is crucial for advancing cancer detection and therapy monitoring. This research explores recent advancements in tumor-targeted SPECT radiotracers, focusing on design optimization and potential pitfalls.

Keywords:
RadiolabelingTracer developmentTumor targetingSPECT

More Related Videos

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

Related Experiment Videos

Last Updated: May 19, 2026

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner
08:36

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Published on: June 7, 2024

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

Area of Science:

  • Nuclear Medicine
  • Radiochemistry
  • Oncology Imaging

Background:

  • Single-photon emission computed tomography (SPECT) is a key nuclear medicine imaging technique.
  • Limited development of new SPECT tracers over the past two decades hinders its full potential in oncology.
  • Effective SPECT imaging for cancer requires radiotracers with specific tumor targeting, high affinity, and rapid clearance.

Purpose of the Study:

  • To review recent developments in tumor-targeted SPECT radiotracers for cancer imaging.
  • To discuss strategies for optimizing SPECT tracer design.
  • To identify potential causes of failure in SPECT tracer development.

Main Methods:

  • Review of recent literature on SPECT radiotracer design for cancer.
  • Analysis of components of target-specific SPECT radiopharmaceuticals (targeting biomolecule, radionuclide, chelator).
  • Discussion of design principles balancing target binding and clearance.

Main Results:

  • Recent progress in developing novel SPECT tracers for various cancer applications.
  • Identification of key factors influencing tracer efficacy, including biomolecule choice and radionuclide selection.
  • Exploration of theranostic approaches combining diagnostic SPECT with therapeutic radionuclides.

Conclusions:

  • Optimized SPECT tracer design is essential for improving cancer diagnosis, staging, and therapy response assessment.
  • Careful consideration of tracer components and their interplay is critical to avoid design failures.
  • Continued innovation in SPECT radiotracer development holds significant promise for advancing oncologic imaging and treatment.